Status:

COMPLETED

A Pilot Study of Ultrasound-guided Vacuum-assisted Excision of Breast Cancers

Lead Sponsor:

Manchester University NHS Foundation Trust

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Brief Summary

This study is looking into whether the procedure called Vacuum Assisted Excision (VAE) is a safe method for the removal of small and medium sized invasive breast cancers in patients who are unfit or h...

Eligibility Criteria

Inclusion

  • The patient is aged 18 years or older.
  • Diagnosis on core needle biopsy of invasive cancer of the breast
  • Unifocal invasive tumour on imaging (hormone receptor positive or negative)
  • T1 or T2 primary or locally recurrent tumour measuring ≤25mm on imaging, excluding any adjacent ductal carcinoma in situ (largest of the measurements on mammography (including digital breast tomosynthesis if performed) and ultrasound)
  • The tumour is clearly visible on ultrasound
  • Vacuum-assisted excision of the entire ultrasonically visible tumour is deemed to be technically feasible
  • The patient is considered to be at high risk of complications or death from a general anaesthetic and therefore surgery under general anaesthesia is not considered appropriate. This must be confirmed by agreement by two named consultant breast surgeons, a multidisciplinary team meeting (including at least one consultant breast surgeon) or by formal anaesthetic assessment. Unsuitability for surgery under local anaesthetic must be confirmed by a consultant breast surgeon.
  • or - The patient refuses to undergo surgery. This must be confirmed by a consultant surgeon and breast care nurse following full discussion of the treatment options.
  • or - The patient is considered unlikely to benefit from surgical removal of the cancer by virtue of known metastatic disease or other life-shortening condition. This must be confirmed by discussion in a multidisciplinary team meeting which includes an oncologist.
  • The patient has given written informed consent for the study Women who are already on primary endocrine therapy for a breast cancer and meet the inclusion criteria will also be eligible.

Exclusion

  • The patient is on anticoagulants or has a known clotting disorder
  • Pregnancy or lactation
  • Allergy to local anaesthetic

Key Trial Info

Start Date :

June 25 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 31 2021

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT04679207

Start Date

June 25 2018

End Date

May 31 2021

Last Update

January 18 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Manchester University NHS Foundation Trust

Manchester, United Kingdom, M13 9WU